Increasing evidence suggests that the brain renin-angiotensin system may play a role in the development of hypertension in the spontaneously hypertensive rat (SHR). Of great importance is the finding that chronic intra-cerebroventricular (icv) treatment of SHR with the converting enzyme inhibitor, captopril, at doses which have no effect when given intravenously significantly attenuates the development of hypertension. The mechanisms underlying this antihypertensive action of captopril and the role of the brain renin-angiotensin system in spontaneous hypertension are not known with certainty. The present research plan proposes to define the role of brain angiotensin II (AII) in SHR and identify its mechanism(s) of action. This proposal will test the hypothesis that brain AII participates in SHR by producing the functional abnormalities in vascular reactivity, baroreflex activity and/or sympathetic drive which characterize this strain. To this end we will employ captopril to block the brain renin-angiotensin system and study the effects of this blockade on the development of functional abnormalities in SHR. Brain angiotensin may produce alterations in vascular reactivity through its ability to affect the release of ACTH and vasopressin. Peripheral vascular reactivity studies (conscious whole animal using Doppler flow probes and isolated perfused vascular beds) will be performed to determine whether corticosterone and/or vasopressin participates in the induction of increased vascular reactivity in SHR and whether the inhibitory effects of centrally administered captopril are due to inhibition of ACTH and/or vasopressin. Brain angiotensin may participate in SHR by altering baroreflex function. This will be tested by assessing the effect of captopril treatment of SHR on baroreflex control of heart rate and vascular resistance and determining whether the effects of captopril are reversed by administration of AII or vasopressin. Finally, brain AII may produce alterations in sympathetic function in SHR. This will be testedly assessing the effects of inhibition of brain AII on sympathetic function and the ability of central AII administration to reverse the effects of blockade. The results of these experiments should provide fundamental information on the role of brain AII in normal cardiovascular regulation as well as in the pathogenesis of hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL031515-02
Application #
3342691
Study Section
Cardiovascular and Pulmonary Research B Study Section (CVB)
Project Start
1983-12-01
Project End
1986-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
School of Medicine & Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Belmadani, Souad; Bernal, Juan; Wei, Chih-Chang et al. (2007) A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 171:777-89
Zhou, Yong; Poczatek, Maria H; Berecek, Kathleen H et al. (2006) Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 339:633-41
Berecek, Kathleen H; Reaves, Phyllis; Raizada, Mohan (2005) Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. Vascul Pharmacol 42:93-8
Fang, Z; Sripairojthikoon, W; Calhoun, D A et al. (1999) Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens 17:983-91
Roysommuti, S; Mozaffari, M S; Berecek, K H et al. (1999) Lifetime treatment with captopril improves renal function in spontaneously hypertensive rats. Clin Exp Hypertens 21:1315-25
Keaton, A K; Clark, J T (1998) Effects of angiotensin II on sexual function, blood pressure, and fluid intake are differentially affected by AT-1 receptor blockade. Physiol Behav 64:339-46
Keaton, A K; White, C R; Berecek, K H (1998) Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Clin Exp Hypertens 20:847-66
Regan, C P; Anderson, P G; Bishop, S P et al. (1997) Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. Am J Physiol 272:H2131-8
Zhang, L; Edwards, D G; Berecek, K H (1996) Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin Exp Hypertens 18:201-26
Berecek, K H; Zhang, L (1995) Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. Adv Exp Med Biol 377:141-68

Showing the most recent 10 out of 24 publications